Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiprogrel for Secondary Prevention After Minor Ischemic Stroke or High-Risk TIA (Phase II, China)
CTR20243166Phase 2Completed
- Sponsor
- Tianjin Institute of Pharmaceutical Research
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of taipugrel in ischemic stroke, transient ischaemic attack (TIA), sponsored by Tianjin Institute of Pharmaceutical Research. Started Sep 2024; status: completed.
02
Drugs
taipugrel
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on CTR20243166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243166.